» Articles » PMID: 23130114

Mortality Rates in Trials of Subjects with Type 2 Diabetes

Overview
Date 2012 Nov 7
PMID 23130114
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In randomized controlled trials (RCTs) of subjects with type 2 diabetes mellitus, mortality rates vary substantially. We sought to examine the inclusion and exclusion criteria of these RCTs to explore relationships with mortality.

Methods And Results: MEDLINE database was searched from August 1980 through March 2011. Selection criterion included published RCTs of adults with type 2 diabetes mellitus of at least 1000 patients, reporting all-cause mortality and having follow-up duration of at least 1 year. Twenty-two trials were eligible. Annualized mortality rates were derived. Inclusion and exclusion criteria were tabulated for each trial. Trials were categorized in 4 groups according to annual mortality rates: <1, ≥1 to <2, ≥2 to <4, and ≥4 per 100 patient-years. The analysis cohort included 91842 patients and 6837 deaths. Mortality rates ranged from 0.28 to 8.24 per 100 patient-years. Patients enrolled in the highest mortality category were more likely to be older and had longer diabetes duration and higher blood pressure. The selection for hypertension was common in the low- as well as high-mortality trials. Although the mortality rates were higher in RCTs with prior cardiovascular morbidity, the selection for chronic kidney disease-defined by either higher serum creatinine or lower estimated glomerular filtration rate and/or the presence of proteinuria-was associated with the highest mortality rates.

Conclusions: In this analysis of RCTs of type 2 diabetes mellitus, a 29-fold difference in annualized mortality was observed. In these RCTs, selection for renal disease, defined by either decline in renal function or presence of proteinuria, portends important mortality risk. (J Am Heart Assoc. 2012;1:8-15.)

Clinical Trial Registration: URL: http://www.ClinicalTrials.gov. Unique identifier: NCT00303979.

Citing Articles

The Role of Mitochondria in Diabetic Kidney Disease and Potential Therapeutic Targets.

Takasu M, Kishi S, Nagasu H, Kidokoro K, Brooks C, Kashihara N Kidney Int Rep. 2025; 10(2):328-342.

PMID: 39990900 PMC: 11843125. DOI: 10.1016/j.ekir.2024.10.035.


Time to first optimal glycemic control and its predictors among adult type 2 diabetes patients in Amhara Regional State comprehensive specialized hospitals, Northwest Ethiopia.

Chalie S, Ewunetie A, Assemie M, Liknaw A, Molla F, Telayneh A BMC Endocr Disord. 2024; 24(1):169.

PMID: 39215294 PMC: 11363452. DOI: 10.1186/s12902-024-01695-1.


Association of the dietary inflammatory index with complicated diabetic kidney disease in people with diabetes mellitus: evidence from NHANES 2009-2018.

Rui Y, Zhang X, Xie H, Qi H, Liu R, Zeng N Acta Diabetol. 2024; 61(11):1375-1384.

PMID: 38847922 DOI: 10.1007/s00592-024-02288-z.


Association between diabetic status and risk of all-cause and cause-specific mortality on dialysis following first kidney allograft loss.

Samarasinghe A, Wong G, Teixeira-Pinto A, Johnson D, Hawley C, Pilmore H Clin Kidney J. 2024; 17(3):sfad245.

PMID: 38468698 PMC: 10926326. DOI: 10.1093/ckj/sfad245.


Identification and validation of immune and cuproptosis - related genes for diabetic nephropathy by WGCNA and machine learning.

Chen Y, Liao L, Wang B, Wu Z Front Immunol. 2024; 15:1332279.

PMID: 38390317 PMC: 10881670. DOI: 10.3389/fimmu.2024.1332279.


References
1.
Solomon S . Cardiovascular clinical trials in patients with diabetes mellitus: lessons from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study. Circulation. 2010; 121(22):2453-5. DOI: 10.1161/CIRCULATIONAHA.109.925875. View

2.
Sjolie A, Klein R, Porta M, Orchard T, Fuller J, Parving H . Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008; 372(9647):1385-93. DOI: 10.1016/S0140-6736(08)61411-7. View

3.
Frye R, August P, Brooks M, Hardison R, Kelsey S, MacGregor J . A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009; 360(24):2503-15. PMC: 2863990. DOI: 10.1056/NEJMoa0805796. View

4.
Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427-43. DOI: 10.1056/NEJMoa066224. View

5.
Cryer D, Nicholas S, Henry D, Mills D, Stadel B . Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care. 2005; 28(3):539-43. DOI: 10.2337/diacare.28.3.539. View